340450 — GC Genome Share Price
Last trade - 00:00- KR₩191bn
- KR₩148bn
- KR₩26bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.59 | ||
| Price to Tang. Book | 2.61 | ||
| Price to Free Cashflow | 855.77 | ||
| Price to Sales | 6.67 | ||
| EV to EBITDA | 65 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1% | ||
| Return on Equity | 0.04% | ||
| Operating Margin | -2.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | n/a | n/a | 24,113.61 | 27,292.05 | 25,887.8 | n/a | n/a | 3.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GC Genome Corp is a Korea-based company principally engaged in the provision of genome testing and analysis services. The Company is principally engaged in the provision of prenatal and newborn screening genetic testing services, cancer patient precision diagnosis genetic testing services, precision diagnosis genetic testing service for patients with rare diseases, health checkup test services as well as others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- August 1st, 2013
- Public Since
- June 11th, 2025
- No. of Employees
- 125
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 23,650,793
- Address
- 107, Ihyeon-ro 30beon-gil, Giheung-gu, YONGIN, 16924
- Web
- https://www.gcgenome.com/
- Phone
- +82 312809900
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 340450
Similar to 340450
Biotoxtech Co
Korea Exchange - KOSDAQ
Chabiotech Co
Korea Exchange - KOSDAQ
DreamCIS
Korea Exchange - KOSDAQ
DT&CRO Co
Korea Exchange - KOSDAQ
GC Cell
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:45 UTC, shares in GC Genome are trading at KR₩8,090. This share price information is delayed by 15 minutes.
Shares in GC Genome last closed at KR₩8,090 and the price had moved by over the past 365 days. In terms of relative price strength the GC Genome share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreGC Genome does not currently pay a dividend.
GC Genome does not currently pay a dividend.
GC Genome does not currently pay a dividend.
To buy shares in GC Genome you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩8,090, shares in GC Genome had a market capitalisation of KR₩191bn.
Here are the trading details for GC Genome:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 340450
Based on an overall assessment of its quality, value and momentum GC Genome is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GC Genome. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of KR₩8,090, shares in GC Genome were trading -5.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GC Genome PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,090.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on GC Genome's directors